Blueprint Medicines (BPMC) Q1 2025 earnings summary

Executive summary

• AYVAKIT net product revenues reached $149.4M in Q1 2025, up 61% year-over-year, with $129.4M from the US and $20M ex-US, reflecting strong commercial momentum and increased patient adoption.

• Full-year 2025 AYVAKIT revenue guidance raised to $700–$720M, targeting $2B by 2030 and $4B peak for the systemic mastocytosis (SM) franchise.

• Advanced pipeline with initiation of BLU-808 proof-of-concept studies and ongoing HARBOR study for elenestinib.

• Cash position strengthened to $899.8M as of March 31, 2025, supporting ongoing R&D and commercial activities.

• Recorded a $50M gain from the sale of the IDRx equity investment in Q1 2025.

Financial highlights

• Q1 2025 total revenues were $149.4M, up from $96.1M in Q1 2024, driven by AYVAKIT/AYVAKYT sales.

• Net income was $0.5M in Q1 2025, compared to $89.1M in Q1 2024, reflecting the absence of prior year one-time gains.

• Cash, cash equivalents, and investments totaled $899.8M as of March 31, 2025, up from $863.9M at year-end 2024.

• Cost of sales decreased to $2.8M from $3.2M year-over-year, despite higher product sales volume.

• R&D expenses rose to $91.9M, and SG&A expenses increased to $95.8M, reflecting expanded commercialization and pipeline investment.

Outlook and guidance

• 2025 AYVAKIT revenue guidance raised to $700–$720M, with a target of $2B by 2030 and $4B peak SM franchise opportunity.

• Expects robust growth in net product revenues for 2025, driven by continued patient uptake and market expansion.

• Anticipates year-over-year reduction in cash burn for 2025 while investing in pipeline programs.

• Existing cash and projected revenues expected to support a self-sustainable financial profile.

• International ISM reimbursement expansion expected to drive future ex-U.S. growth.